Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
The U.S. Federal Trade Commission cautioned Novo Nordisk that its proposed acquisition of Metsera may breach premerger review laws under the Hart-Scott-Rodino Act.
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.
Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
